Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that oral administration of Lactococcus lactis subsp. cremoris H61 to aged mice was associated with reduced bone loss, fewer skin ulcers, and less hair loss compared with controls.

This consensus summary suggests that 5-alpha reductase inhibitors have clear benefits for benign prostatic hyperplasia, but their impact on prostate cancer prevention is still debated.

This study found that some patients with alopecia areata who did not respond to ritlecitinib treatment by Week 24 achieved a positive response with continued therapy by Week 48, with tolerable side effects.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.

Choose IPL for versatility and speed, ruby lasers for precision.

This study suggests that compounds from Sansevieria trifasciata Prain may have promising potential as effective 5α-reductase inhibitors for alopecia treatment, outperforming finasteride in binding affinity tests.

This review highlights that 5 Alpha Reductase Inhibitors, used for treating conditions like benign prostatic hypertrophy, can cause side effects that sometimes persist after stopping the medication, urging physicians to consider these drugs as potential sources of new symptoms in patients.

This study found that medications including benzodiazepines, quetiapine, and certain alpha-blockers, along with hypertension and short axial length, were independently associated with an increased risk of Intraoperative Floppy Iris Syndrome during cataract surgery.

This review analyzed the use of 5-alpha reductase inhibitors (5ARIs) for treating various dermatological conditions such as androgenetic alopecia, acne, and hirsutism, emphasizing their efficacy and safety profile.

This report presents the first documented case of CARASIL in an Arabic patient and notes unique magnetic resonance spectroscopy findings compared to prior cases.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This study explored the potential use of natural ingredients in managing alopecia areata, investigating their safety and efficacy as alternatives to conventional chemical treatments.

In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

This study found that patients with RASopathies have lower serum IgA and CD8 levels compared to controls, indicating a potential risk for developing autoimmune disorders.

This study found that patients with RASopathies demonstrated lower levels of serum IgA and CD8 T cells compared to controls, potentially indicating an increased risk of developing autoimmune disorders.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This study found that current use of benzodiazepines, α1-blockers (like tamsulosin, alfuzosin, terazosin), finasteride, and possibly rivastigmine is associated with increased risk of intraoperative floppy iris syndrome in cataract surgery patients.

JAK inhibitors are generally safe for treating alopecia areata.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

This study found that 5-alpha-reductase inhibitors were associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.

This review discusses the approved uses and adverse reactions of JAK inhibitors, noting their importance in treating various conditions but highlighting significant hematological and immunological risks.

In this integrative narrative review, researchers reported that aromatase inhibition using dutasteride and Serenoa repens after hair transplant can effectively preserve follicles and minimize side effects, suggesting personalized strategies may optimize clinical outcomes and patient satisfaction.

In this study, researchers found that the AIRE G961C variant is a significant risk factor for severe alopecia areata and early-onset cases, particularly in patients with alopecia universalis.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This source reports that JAK inhibitors, such as ruxolitinib, baricitinib, and tofacitinib, have led to hair regrowth in alopecia areata patients and animal models, but their long-term safety and effectiveness remain uncertain, with ongoing trials to further investigate these factors.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.